| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
|
|
|
||||||
|
||||||||
Stem Cell Transplantation |
1 Service d’Hématologie Clinique, CHU Hôtel Dieu, Université de Nantes, Nantes, France;
2 European Group for Blood and Marrow Transplantation (EBMT), Acute Leukemia Working Party, Hopital Saint-Antoine, Assistance Publique des Hôpitaux de Paris and Université de Paris 6, Pierre et Marie Curie, Paris, France;
3 Centre Hospitalo-Universitaire de Bordeaux, Hôpital Haut-Leveque, Pessac, France;
4 University Hospital, Dept. of Hematology, Linköping, Sweden;
5 Klinik fuer Knochenmarktransplantation und Haematologie/Onkologie, Idar-Oberstein, Germany;
6 Ospedale Bergamo, Divisione di Ematologia, Bergamo, Italy;
7 University Hospital Gasthuisberg, Dept. of Hematology, Leuven, Belgium;
8 Hadassah University Hospital, Department of Bone Marrow Transplantation, Jerusalem, Israel;
9 Ospedale S. Camillo-Forlanini, Dept. of Hematology and BMT, Rome, Italy;
10 Tel-Aviv University, Chaim Sheba Medical Center, Tel-Hashomer, Israel;
11 Unité de Transplantation et de Thérapie Cellulaire, Institut Paoli-Calmettes, Marseille, France and
12 Department of Hematology, Hopital Saint-Louis, Assistance Publique Hopitaux de Paris, Paris, France
Correspondence: Mohamad Mohty, M.D., Ph.D., Service d’Hématologie Clinique, CHU Hôtel-Dieu, Université de Nantes, Place Alexis Ricordeau, F-44093 Nantes, France. E-mail: mohamad.mohty{at}univ-nantes.fr
This retrospective study reported the outcome of 97 adult acute lymphoblastic leukemia patients who received a reduced-intensity conditioning allogeneic stem cell transplantation. With a median follow-up of 2.8 years, two year overall-survival, leukemia-free survival and non-relapse mortality were significantly better in patients transplanted in first complete remission (CR1, 52±9%; 42±10%; and 18±7% respectively) compared with those transplanted in more advanced phase (p=0.003, p=0.002 and p=0.01 respectively). In multivariate analysis, disease status (CR1 vs. advanced; p=0.001) and chronic graft-vs-host disease (p=0.01) were associated with an improved overall-survival, suggesting that reduced-intensity conditioning allogeneic stem cell transplantation is feasible in patients with high risk lymphoblastic leukemia in remission at transplantation.
Key words: allogeneic SCT, acute lymphoblastic leukemia.
This article has been cited by other articles:
|
|
 |
|
  A. K. Fielding, J. M. Rowe, S. M. Richards, G. Buck, A. V. Moorman, I. J. Durrant, D. I. Marks, A. K. McMillan, M. R. Litzow, H. M. Lazarus, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993 Blood, May 7, 2009; 113(19): 4489 - 4496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Bachanova, M. R. Verneris, T. DeFor, C. G. Brunstein, and D. J. Weisdorf Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation Blood, March 26, 2009; 113(13): 2902 - 2905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fielding The Treatment of Adults with Acute Lymphoblastic Leukemia Hematology, January 1, 2008; 2008(1): 381 - 389. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
